Barinthus Biotherapeutics (NASDAQ:BRNS) Receives “Buy” Rating from HC Wainwright

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 270.37% from the stock’s previous close.

Separately, Alliance Global Partners reduced their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Down 8.3 %

Barinthus Biotherapeutics stock opened at $1.35 on Friday. Barinthus Biotherapeutics has a twelve month low of $1.11 and a twelve month high of $4.16. The stock has a market cap of $53.22 million, a P/E ratio of -0.91 and a beta of -0.59. The company’s 50-day moving average price is $1.29 and its two-hundred day moving average price is $1.57.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same period in the previous year, the business earned ($0.37) EPS. Equities analysts anticipate that Barinthus Biotherapeutics will post -1.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Catalina Capital Group LLC bought a new position in shares of Barinthus Biotherapeutics in the 2nd quarter valued at $25,000. Ipswich Investment Management Co. Inc. acquired a new position in Barinthus Biotherapeutics in the 2nd quarter worth about $32,000. BlueCrest Capital Management Ltd bought a new position in Barinthus Biotherapeutics in the first quarter valued at about $1,292,000. DC Funds LP acquired a new stake in shares of Barinthus Biotherapeutics during the first quarter valued at about $1,528,000. Finally, Alphabet Inc. bought a new stake in shares of Barinthus Biotherapeutics during the second quarter worth about $2,119,000. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.